ANVISA certifies Bhayla OSD and hormone facilities for Brazil

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹2030.00

prior close

₹2036.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+1.6% vs market

Pharmaceuticals peers, median of 170sector-0.5%+1.1% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.5

15m

+0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6-1.0+1.6-0.5+1.1

Next day

+1.0-3.3+4.3-2.2+3.2

+0.5-2.9+3.5-1.1+1.6

+6.2pendingpending+0.7+5.5

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Corona Remedies received Good Manufacturing Practice compliance certification from Brazil's health regulator, ANVISA, for its oral solid dosage and hormone manufacturing facilities in Bhayla, Ahmedabad. This may support access to the Brazilian market, but the filing gives no details on orders, revenue or financial impact.

Likely market impact

Positive for manufacturing credibility and potential Brazil market access, but no immediate revenue or order impact is disclosed.